All In Biotech

Drug Trial Radar · NCT06833073

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

308

Planned (sponsor's estimate)

Start

Mar 11, 2025

Primary completion

Sep 3, 2031

Study completion Sep 3, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.

Conditions

  • Urinary Bladder Neoplasms
  • Non-Muscle Invasive Bladder Neoplasms
  • Carcinoma in Situ

Interventions

  • Intismeran autogeneBiological

    IM injection

  • BCGBiological

    Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Event-free Survival (EFS)Time frame: Up to approximately 5 years

Locations

89 sites in 19 countries. Site status is shown where the registry gives one.

  • Michael G Oefelein Clinical Trials ( Site 0138)

    Bakersfield, California · Recruiting

  • Genesis Research, LLC ( Site 0141)

    Los Alamitos, California · Active not recruiting

  • USC Norris Comprehensive Cancer Center ( Site 0123)

    Los Angeles, California · Recruiting

  • Genesis Healthcare-Torrance ( Site 0140)

    Torrance, California · Recruiting

  • Genesis Research LLC ( Site 0118)

    Torrance, California · Recruiting

  • Urology Associates ( Site 0144)

    Littleton, Colorado · Recruiting

  • Urological Research Network ( Site 0133)

    Hialeah, Florida · Recruiting

  • Associated Urological Specialists - Chicago Ridge ( Site 0139)

    Chicago Ridge, Illinois · Recruiting

  • Southern Urology, LLC ( Site 0145)

    Lafayette, Louisiana · Recruiting

  • University of Missouri Health Care ( Site 0126)

    Columbia, Missouri · Recruiting

  • NHO Revive Research Institute, LLC ( Site 0137)

    Lincoln, Nebraska · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111)

    New York, New York · Recruiting

  • TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122)

    Cincinnati, Ohio · Recruiting

  • OHSU Knight Cancer Institute - South Waterfront ( Site 0110)

    Portland, Oregon · Recruiting

  • MidLantic Urology ( Site 0102)

    Bala-Cynwyd, Pennsylvania · Recruiting

  • The Conrad Pearson Clinic ( Site 0143)

    Germantown, Tennessee · Recruiting

  • Texas Oncology-Austin Central ( Site 0107)

    Austin, Texas · Recruiting

  • Urology Austin, PLLC ( Site 0109)

    Austin, Texas · Recruiting

  • Urology of Virginia ( Site 0125)

    Virginia Beach, Virginia · Recruiting

  • University of Washington - Fred Hutchinson Cancer Center ( Site 0100)

    Seattle, Washington · Recruiting

  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0301)

    La Rioja, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires ( Site 0307)

    CABA, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0306)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Mar de Plata ( Site 0305)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0303)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Fundacion Estudios Clinicos ( Site 0304)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Sanatorio Parque ( Site 0300)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Macquarie University ( Site 1801)

    Macquarie University, New South Wales, Australia · Recruiting

  • Fiona Stanley Hospital ( Site 1803)

    Perth, Western Australia, Australia · Recruiting

  • Instituto do Câncer e Transplante de Curitiba ( Site 0402)

    Curitiba, Paraná, Brazil · Recruiting

  • Hospital de Clínicas de Passo Fundo ( Site 0406)

    Passo Fundo, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0400)

    Barretos, São Paulo, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0410)

    São Jose Do Rio Preto, São Paulo, Brazil · Recruiting

  • The Moncton Hospital-Oncology ( Site 0200)

    Moncton, New Brunswick, Canada · Recruiting

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0204)

    Sherbrooke, Quebec, Canada · Recruiting

  • Bradford Hill Norte ( Site 0503)

    Antofagasta, Chile · Recruiting

  • Oncocentro Valdivia ( Site 0507)

    Valdivia, Los Ríos Region, Chile · Recruiting

  • Fundación Arturo López Pérez ( Site 0500)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 0502)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0501)

    Santiago, Region M. de Santiago, Chile · Recruiting

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.